Шрифт:
Закладка:
87
https://www.thelancet.com/commissions/global-mental-health
88
https://www.who.int/news-room/fact-sheets/detail/depression
89
DALY, disability-adjusted life year, – потенциальный год жизни, утраченный из-за преждевременной смерти, инвалидности или слабого здоровья, рассчитывается, как сумма двух слагаемых: YLL (Years Life Lost – потери, обусловленные смертностью) и YLD (Years Lost due to Disability – потери здоровья, обусловленные нетрудоспособностью). Global Health Estimates 2019: 20 Leading Causes of DALY globally, 2019 and 2000.
90
Merikangas KR, He J, Burstein M, et al. Lifetime Prevalence of Mental Disorders in US Adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). Journal of the American Academy of Child and Adolescent Psychiatry. 2010; 49(10): 980–989. doi:10.1016/j.jaac.2010.05.017
91
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U. S. Department of Health and Human Services; 2014
92
Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS data brief, no 94. Hyattsville, MD: National Center for Health Statistics. 2012
93
Prevalence of mood disorders in the rural population of Udmurtia. Pakriev, Acta Psychiatr Scand. 1998 Mar; 97(3): 169–74
94
Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995; 4: 99–105
95
МКБ-11.
96
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994
97
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992
98
Tsuang MT, Taylor L, Faraone SV. An overview of the genetics of psychotic mood disorders. J Psychiatr Res. 2004; 38: 3–15
99
Nutt DJ (2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". Journal of Clinical Psychiatry. 69 Suppl E1: 4–7
100
Merzenich MM, Nelson RJ, Stryker MP, Cynader MS, Schoppmann A, Zook JM. Somatosensory cortical map changes following digit amputation in adult monkeys. J Comp Neurol. 1984; 224(4): 591–605.
101
Davidson RJ, McEwen BS. Social influences on neuroplasticity: Stress and interventions to promote well-being. Nature neuroscience. 2012; 15(5): 689–695. doi: 10.1038/nn. 3093
102
Castrén E, Rantamäki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp. 2008; 289: 43–52
103
Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010; 70(5): 289–97
104
Goldman-Rakic PS (October 1996). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 351(1346): 1445–53
105
X. T. Wang and Robert D. Dvorak. Sweet Future: Fluctuating Blood Glucose Levels Affect Future Discounting. Psychological Science, 21, 183–188
106
Maes M. "Functional" or "psychosomatic" symptoms, e. g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett. 2009; 30(5): 564–73
107
Ryan KA, Dawson EL, Kassel MT, et al. Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders. Brain. 2015; 138(Pt 5): 1424–34
108
Mackin P, Young AH, The Role of Cortisol and Depression: Exploring New Opportunities for Treatments, Psychiatric Times, 2004; 21: 92–5
109
Касьянов Е. Д., Мазо Г. Э. Функционирование гипоталамо-гипофизарно-надпочечниковой оси при депрессии: актуальное состояние проблемы. // Психическое здоровье. 2017. № 8. С. 27–34.
110
Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med. 2013; 43(3): 449–69.
111
Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(22): 12320–12322
112
D'Mello, C., and Swain, M. G. (2017). Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr.
113
https://www.nature.com/articles/s41398–021–01302–0?utm_medium=affiliate&utm_source=commission_junction&utm_campaign=3_nsn6445_deeplink_PID100029727&utm_content=deeplink.
114
Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. Hay PJ, ed. PLoS Medicine. 2013; 10(11): e1001547
115
Соломон Э. Демон полуденный: Анатомия депрессии. – М.: Добрая книга, 2004
116
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169764
117
Lorant V, Deliege D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157:98–112.
118
Jonassen R, Chelnokova O, Harmer C, Leknes S, Landrø NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology (Berl). 2015; 232(5): 953–8.
119
Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest. 1952; 21(4): 385–438
120
Burn JH. The Antihistamine Compounds. British Medical Journal. 1958; 2(5100): 845–846
121
Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991; 47(1): 4–8
122
Fagius J, Osterman PO, Sidén A, Wiholm
